Half-year report · HY
3341.TEDINET S100X3D6
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥191.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥360.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥175.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥4.2bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥423m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥4.2bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥6.9bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥772m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.0bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥762m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥43m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.1bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥43m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥210.3bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥197.1bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥204.1bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥150.5bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥138.0bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥59.8bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥59.1bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥57.9bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥16.5bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥27.5bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥16.5bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥27.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥5.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥8.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥3.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥9.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥4.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥37.06 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.54 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.44 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 28.4% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥6.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥6.5bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥3.4bn |
| Dispensing Pharmacy Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥172.0bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥172.0bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥7.3bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.7bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.7bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥9m |
| Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥388m |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥20.4bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥14.0bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.5bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥122m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥198.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥191.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥7.5bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥6.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥6.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥4.2bn |
| Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥156.6bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥156.6bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.5bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥6.0bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.9bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥122m |
| Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥766m |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥19.6bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥13.1bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.5bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥652m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥182.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥175.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥4.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 529
| Item | Context | Value | Unit |
|---|---|---|---|
| Comparative period end date | FilingDateInstant | 2024-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所(プライム市場) | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株(注) | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | InterimInstant_No1MajorShareholdersMember | Original text (Japanese)株式会社AP86 | |
| Address major shareholders | InterimInstant_No1MajorShareholdersMember | Original text (Japanese)東京都港区虎ノ門4丁目1-28 虎ノ門タワーズオフィス17階 | |
| Name major shareholders | InterimInstant_No2MajorShareholdersMember | Original text (Japanese)株式会社マックスプランニング | |
| Address major shareholders | InterimInstant_No2MajorShareholdersMember | Original text (Japanese)東京都港区西麻布4丁目19-6 | |
| Name major shareholders | InterimInstant_No3MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行株式会社（信託口） | |
| Address major shareholders | InterimInstant_No3MajorShareholdersMember | Original text (Japanese)東京都港区赤坂1丁目8番1号 赤坂インターシティAIR | |
| Name major shareholders | InterimInstant_No4MajorShareholdersMember | Original text (Japanese)株式会社日本カストディ銀行（信託口） | |
| Address major shareholders | InterimInstant_No4MajorShareholdersMember | Original text (Japanese)東京都中央区晴海1丁目8-12 | |
| Name major shareholders | InterimInstant_No5MajorShareholdersMember | Original text (Japanese)NOMURA INTERNATIONAL PLC A/C JAPAN FLOW （常任代理人 野村證券株式会社） | |
| Address major shareholders | InterimInstant_No5MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No6MajorShareholdersMember | Text · Plus | |
| Address major shareholders | InterimInstant_No6MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No7MajorShareholdersMember | Original text (Japanese)JP MORGAN CHASE BANK 385781 （常任代理人 株式会社みずほ銀行決済営業部） | |
| Address major shareholders | InterimInstant_No7MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No8MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行株式会社（役員報酬BIP信託口・76610口） | |
| Address major shareholders | InterimInstant_No8MajorShareholdersMember | Original text (Japanese)東京都港区赤坂1丁目8番1号 赤坂インターシティAIR | |
| Name major shareholders | InterimInstant_No9MajorShareholdersMember | Text · Plus | |
| Address major shareholders | InterimInstant_No9MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No10MajorShareholdersMember | Original text (Japanese)みずほ証券株式会社 | |
| Address major shareholders | InterimInstant_No10MajorShareholdersMember | Original text (Japanese)東京都千代田区大手町1丁目5番1号 | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | InterimInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | InterimInstant_OrdinarySharesSharesLessThanOneUnitMember | Original text (Japanese)一単元(100株)未満の株式 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |